Otolaryngol Head Neck Surg 2012 Jan 20;146(1):173-4. Epub 2011 Jun 20.
Department of Otolaryngology-Head & Neck Surgery, Tripler Army Medical Center, Hawaii, USA.
J Am Acad Dermatol 2021 Jul 31. Epub 2021 Jul 31.
Dermatopathology Unit, Department of Pathology, Massachusetts General Hospital, Boston MA.
Ann Pharmacother 2021 Aug 2:10600280211026338. Epub 2021 Aug 2.
Union University College of Pharmacy, Jackson, TN, USA.
Objective: To identify and assess the current literature surrounding the safety, efficacy, and practical considerations of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (r/r) mantle cell lymphoma (MCL).Data Sources: An English-based literature search was conducted using the terms "" AND "" OR ""in PubMed (inception through May 1, 2021), EMBASE (inception through May 1, 2021), and ClinicalTrials.gov. Read More
Arch Med Sci 2021 18;17(4):920-927. Epub 2019 Feb 18.
Department of Medical Oncology, Anatolian Health Center, Istanbul, Turkey.
Introduction: We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey.Material And Methods: In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity. Read More
Clin Ther 2021 Jul 28. Epub 2021 Jul 28.
Janssen Scientific Affairs LLC, Horsham, Pennsylvania.
Purpose: This study assessed treatment patterns in patients with mantle cell lymphoma (MCL) and compared health care resource utilization (HRU) and costs of ibrutinib with or without rituximab (I ± R) versus chemoimmunotherapy (CIT) in patients with relapsed/refractory MCL.Methods: For this retrospective cohort study, adults with MCL observed between May 13, 2013, and June 30, 2019, were identified using Optum's de-identified Clinformatics Data Mart Database. Treatment patterns were described among patients who received ≥1 line of therapy (LOT). Read More
Leuk Res 2021 Jul 24;111:106672. Epub 2021 Jul 24.
Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. Electronic address:
Mantle cell lymphoma (MCL) is usually resistant to the current standard-of-care regimens and also to novel agents such as the proteasome inhibitor bortezomib. A better prognosis of leukemic variants of MCL suggests that MCL cells acquire drug resistance in nodal and/or bone marrow microenvironments via interaction with supporting cells. Bortezomib exerts cytotoxic action in MCL cells via stabilization of the pro-apoptotic BCL-2 family protein NOXA. Read More